Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)
- PMID: 26488473
- DOI: 10.1159/000439290
Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)
Abstract
Intermediate stage hepatocellular carcinoma (HCC) is a very heterogeneous tumor in terms of tumor size (>3 cm ∼ over 10 cm), tumor number (4 ∼ over 20) and liver function (Child-Pugh score 5-9). However, transarterial chemoembolization is the only recommended treatment option according to the Barcelona Clinic Liver Cancer (BCLC) staging. Bolondi's subclassification of BCLC B stage is feasible; however, there are several weak points. Therefore, by modifying Bolondi's subclassification, we have proposed a more simplified subclassification, Kinki criteria. The Kinki criteria consist of 2 factors: liver function (Child-Pugh score 5-7 or 8, 9) and tumor status (Beyond Milan and within up-to-7 criteria; IN and OUT). The Kinki criteria classifies BCLC B stage from B1 (Child-Pugh score 5-7 and within up-to-7), B2 (Child-Pugh score 5-7 and beyond up-to-7) and B3 (Child-Pugh score 8, 9 and any tumor status). These criteria are simple and easy to apply to clinical practice. Therefore, these criteria will stratify the heterogeneous population of BCLC B group patient well and give the treatment indication according to each substage. These criteria should be further validated both retrospectively and prospectively.
© 2015 S. Karger AG, Basel.
Similar articles
-
Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.Dig Dis. 2017;35(6):583-588. doi: 10.1159/000480186. Epub 2017 Oct 17. Dig Dis. 2017. PMID: 29040991
-
Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients.Cancer Res Treat. 2019 Jan;51(1):65-72. doi: 10.4143/crt.2018.038. Epub 2018 Feb 26. Cancer Res Treat. 2019. PMID: 29510616 Free PMC article.
-
Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.Dig Dis. 2016;34(6):671-678. doi: 10.1159/000448834. Epub 2016 Oct 17. Dig Dis. 2016. PMID: 27750236
-
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.Semin Liver Dis. 2012 Nov;32(4):348-59. doi: 10.1055/s-0032-1329906. Epub 2013 Feb 8. Semin Liver Dis. 2012. PMID: 23397536 Review.
-
Treatment of Hepatocellular Carcinoma.Dig Dis. 2016;34(5):597-602. doi: 10.1159/000445275. Epub 2016 Jun 22. Dig Dis. 2016. PMID: 27332893 Review.
Cited by
-
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).Liver Cancer. 2021 Jul 12;10(5):451-460. doi: 10.1159/000516605. eCollection 2021 Sep. Liver Cancer. 2021. PMID: 34721507 Free PMC article.
-
The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma.Ann Surg Open. 2022 May 2;3(2):e163. doi: 10.1097/AS9.0000000000000163. eCollection 2022 Jun. Ann Surg Open. 2022. PMID: 37601608 Free PMC article.
-
A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.BMC Cancer. 2020 Jun 1;20(1):504. doi: 10.1186/s12885-020-06975-2. BMC Cancer. 2020. PMID: 32487089 Free PMC article.
-
Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization.J Hepatocell Carcinoma. 2020 Oct 14;7:181-189. doi: 10.2147/JHC.S273929. eCollection 2020. J Hepatocell Carcinoma. 2020. PMID: 33117752 Free PMC article.
-
Model Predicting Survival in Intermediate-Stage HCC Patients Reclassified for TACE Based on the 2022 BCLC Criteria.Cancers (Basel). 2025 Mar 5;17(5):894. doi: 10.3390/cancers17050894. Cancers (Basel). 2025. PMID: 40075741 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical